SteraMist will present its iHP technology through live demonstrations, highlighting the significant advancements it provides to the pharmaceutical industry. Experts will be available to provide insights and discuss tailored solutions to integrate SteraMist iHP disinfection technology. Explore the latest innovations from SteraMist, including the NV+ and the SteraMist Integrated System (SIS), the newest additions to the product line.
"Interphex stands out as one of the year's most significant pharmaceutical conferences. We are thrilled to unveil the NV+ and the SIS at this event, as these products meet and exceed the current disinfection demands of the life sciences industry," remarks
Don't miss the chance to connect, exchange professional insights, and discover how SteraMist can enhance your decontamination protocols. Join us at SteraMist, booth 2445.
TOMI™
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to corporate service contracts with partners. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our
INVESTOR RELATIONS CONTACT:
IMS Investor Relations
tomi@imsinvestorrelations.com
Source:
2024 GlobeNewswire, Inc., source